Celiac Disease pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook
2020 Celiac Disease PIPELINE HIGHLIGHTS
Celiac Disease is one of the widely researched conditions during 2020 with 19 companies actively focusing on realizing pipeline’s potential. Development of Celiac Disease medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Celiac Disease market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Celiac Disease.
Good progress is anticipated during 2020 and 2021 with Celiac Disease pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Celiac Disease pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Celiac Disease DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Celiac Disease pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Celiac Disease pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
The competitive intelligence report on Celiac Disease presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Celiac Disease pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Celiac Disease DRUG PROFILES
Celiac Disease development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
Both small size and large size pharmaceutical companies are investing their resources in Celiac Disease drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Celiac Disease. Partnerships and acquisitions are also increasingly observed in the pipeline.
This research report presents an analysis of 19 Celiac Disease companies including company overview, key snapshot, contact information, and their strategies on accelerating Celiac Disease pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.
Companies analyzed in the report include- Ahead Therapeutics SL, Amgen Inc, Amyra Biotech AG, Anokion SA, AnTolRx Inc, Bioniz Therapeutics Inc, GlaxoSmithKline Plc, IM Therapeutics LLC, ImmunogenX LLC, ImmusanT Inc, Innovate Biopharmaceuticals Inc, Intrexon Corp , Parvus Therapeutics Inc, Precigen Inc, Takeda Pharmaceutical Company Ltd, Theravance Biopharma Inc, Topas Therapeutics GmbH, Vactech Oy, Zedira GmbH
REASONS TO BUY
Celiac Disease is one of the widely researched conditions during 2020 with 19 companies actively focusing on realizing pipeline’s potential. Development of Celiac Disease medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Celiac Disease market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Celiac Disease.
Good progress is anticipated during 2020 and 2021 with Celiac Disease pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Celiac Disease pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Celiac Disease DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Celiac Disease pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Celiac Disease pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
The competitive intelligence report on Celiac Disease presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Celiac Disease pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Celiac Disease DRUG PROFILES
Celiac Disease development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
- Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
- Phase of development
- Mechanism of Action
- Route of Administration
- Companies involved including originator, licensing companies, developer, investors, and others
- New molecular entity details
- Orphan drug designation and other special status provided by regulators
Both small size and large size pharmaceutical companies are investing their resources in Celiac Disease drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Celiac Disease. Partnerships and acquisitions are also increasingly observed in the pipeline.
This research report presents an analysis of 19 Celiac Disease companies including company overview, key snapshot, contact information, and their strategies on accelerating Celiac Disease pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.
Companies analyzed in the report include- Ahead Therapeutics SL, Amgen Inc, Amyra Biotech AG, Anokion SA, AnTolRx Inc, Bioniz Therapeutics Inc, GlaxoSmithKline Plc, IM Therapeutics LLC, ImmunogenX LLC, ImmusanT Inc, Innovate Biopharmaceuticals Inc, Intrexon Corp , Parvus Therapeutics Inc, Precigen Inc, Takeda Pharmaceutical Company Ltd, Theravance Biopharma Inc, Topas Therapeutics GmbH, Vactech Oy, Zedira GmbH
REASONS TO BUY
- The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
- This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
- Buyers can identify most promising drug candidates for treatment of Celiac Disease
- It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
- Users can estimate possible delays in the delivery of pipeline or launch of new products
- Stay ahead of competition through understanding their pipeline progression, strategies and outlook
- The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
- Optimize your licensing and technology transfer strategies through identification of prospect partners
1. INTRODUCTION TO CELIAC DISEASE
1.1 Celiac Disease- Disease overview
1.2 Celiac Disease- Market Size
1.3 Celiac Disease- Companies Involved
2. CELIAC DISEASE PIPELINE SNAPSHOT- 2020
2.1 Celiac Disease Pipeline by Phase
2.2 Celiac Disease Pipeline by Mechanism of Action
2.3 Celiac Disease Pipeline by Route of Administration
2.4 Celiac Disease Pipeline- New Molecular Entities
2.5 Celiac Disease Pipeline- Orphan Drug Designation/ Special Designation
3. CELIAC DISEASE DRUG PROFILES
3.1 Current Status
3.2 Celiac Disease Drug Snapshot
3.3 Celiac Disease Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Ahead Therapeutics SL Celiac Disease Pipeline Insights and Clinical Trials
4.2 Amgen Inc Celiac Disease Pipeline Insights and Clinical Trials
4.3 Amyra Biotech AG Celiac Disease Pipeline Insights and Clinical Trials
4.4 Anokion SA Celiac Disease Pipeline Insights and Clinical Trials
4.5 AnTolRx Inc Celiac Disease Pipeline Insights and Clinical Trials
4.6 Bioniz Therapeutics Inc Celiac Disease Pipeline Insights and Clinical Trials
4.7 GlaxoSmithKline Plc Celiac Disease Pipeline Insights and Clinical Trials
4.8 IM Therapeutics LLC Celiac Disease Pipeline Insights and Clinical Trials
4.9 ImmunogenX LLC Celiac Disease Pipeline Insights and Clinical Trials
4.10 ImmusanT Inc Celiac Disease Pipeline Insights and Clinical Trials
4.11 Innovate Biopharmaceuticals Inc Celiac Disease Pipeline Insights and Clinical Trials
4.12 Intrexon Corp Celiac Disease Pipeline Insights and Clinical Trials
4.13 Parvus Therapeutics Inc Celiac Disease Pipeline Insights and Clinical Trials
4.14 Precigen Inc Celiac Disease Pipeline Insights and Clinical Trials
4.15 Takeda Pharmaceutical Company Ltd Celiac Disease Pipeline Insights and Clinical Trials
4.16 Theravance Biopharma Inc Celiac Disease Pipeline Insights and Clinical Trials
4.17 Topas Therapeutics GmbH Celiac Disease Pipeline Insights and Clinical Trials
4.18 Vactech Oy Celiac Disease Pipeline Insights and Clinical Trials
4.19 Zedira GmbH Celiac Disease Pipeline Insights and Clinical Trials
5. CELIAC DISEASE MARKET NEWS AND UPDATES
6. APPENDIX
6.1 Sources and Methodology
6.2 Contact Information
1.1 Celiac Disease- Disease overview
1.2 Celiac Disease- Market Size
1.3 Celiac Disease- Companies Involved
2. CELIAC DISEASE PIPELINE SNAPSHOT- 2020
2.1 Celiac Disease Pipeline by Phase
2.2 Celiac Disease Pipeline by Mechanism of Action
2.3 Celiac Disease Pipeline by Route of Administration
2.4 Celiac Disease Pipeline- New Molecular Entities
2.5 Celiac Disease Pipeline- Orphan Drug Designation/ Special Designation
3. CELIAC DISEASE DRUG PROFILES
3.1 Current Status
3.2 Celiac Disease Drug Snapshot
3.3 Celiac Disease Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Ahead Therapeutics SL Celiac Disease Pipeline Insights and Clinical Trials
4.2 Amgen Inc Celiac Disease Pipeline Insights and Clinical Trials
4.3 Amyra Biotech AG Celiac Disease Pipeline Insights and Clinical Trials
4.4 Anokion SA Celiac Disease Pipeline Insights and Clinical Trials
4.5 AnTolRx Inc Celiac Disease Pipeline Insights and Clinical Trials
4.6 Bioniz Therapeutics Inc Celiac Disease Pipeline Insights and Clinical Trials
4.7 GlaxoSmithKline Plc Celiac Disease Pipeline Insights and Clinical Trials
4.8 IM Therapeutics LLC Celiac Disease Pipeline Insights and Clinical Trials
4.9 ImmunogenX LLC Celiac Disease Pipeline Insights and Clinical Trials
4.10 ImmusanT Inc Celiac Disease Pipeline Insights and Clinical Trials
4.11 Innovate Biopharmaceuticals Inc Celiac Disease Pipeline Insights and Clinical Trials
4.12 Intrexon Corp Celiac Disease Pipeline Insights and Clinical Trials
4.13 Parvus Therapeutics Inc Celiac Disease Pipeline Insights and Clinical Trials
4.14 Precigen Inc Celiac Disease Pipeline Insights and Clinical Trials
4.15 Takeda Pharmaceutical Company Ltd Celiac Disease Pipeline Insights and Clinical Trials
4.16 Theravance Biopharma Inc Celiac Disease Pipeline Insights and Clinical Trials
4.17 Topas Therapeutics GmbH Celiac Disease Pipeline Insights and Clinical Trials
4.18 Vactech Oy Celiac Disease Pipeline Insights and Clinical Trials
4.19 Zedira GmbH Celiac Disease Pipeline Insights and Clinical Trials
5. CELIAC DISEASE MARKET NEWS AND UPDATES
6. APPENDIX
6.1 Sources and Methodology
6.2 Contact Information
